B-Raf Is Dispensable for K-Ras-Mediated Oncogenesis in Human Cancer Cells 1

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Research

• Publication date

  2004-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-03-3862PMID 15026326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• It ain't over 'til it's over.

  2005cited by this paper
• Human Somatic Cell Gene Targeting

  2003cited by this paper
• Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis.

  2003cited by this paper
• Raf proteins and cancer: B-Raf is identified as a mutational target.

  2003cited by this paper
• Suppression of BRAF(V599E) in human melanoma abrogates transformation.

  2003cited by this paper
• ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status

  2002cited by this paper
• Distinct requirements for Ras oncogenesis in human versus mouse cells.

  2002cited by this paper
• Stable suppression of tumorigenicity by virus-mediated RNA interference.

  2002cited by this paper
• A genome-wide survey of RAS transformation targets

  2000cited by this paper
• Understanding Ras: 'it ain't over 'til it's over'.

  2000cited by this paper
• Essential role for oncogenic Ras in tumour maintenance

  1999cited by this paper
• Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells

  1999cited by this paper
• Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases*

  1997cited by this paper
• Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*)

  1995cited by this paper
• Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma.

  1993cited by this paper
• Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

  1993cited by this paper
• Establishment of a cell line of human endometrial adenocarcinoma in vitro.

  1972cited by this paper

• Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations

  2021cites this paper
• Isoform-specific Ras signaling is growth factor dependent

  2019cites this paper
• Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo

  2018cites this paper
• The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux

  2015cites this paper
• Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations

  2015cites this paper
• Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.

  2014cites this paper
• Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer

  2014cites this paper
• Use of an ex vivo model of human colorectal tumours to study response to the MEK1/2 inhibitor AZD6244

  2013cites this paper
• A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.

  2013cites this paper
• Virus-mimicking optical nanomaterials: near infrared absorption and fluorescence characteristics and physical stability in biological environments.

  2013cites this paper
• The role of FOXO3a in the cellular stress response and metabolism of breast cancer cells

  2012cites this paper
• Identification of Mutant K-Ras-dependent Phenotypes Using a Panel of Isogenic Cell Lines*

  2012cites this paper
• Human LIGIV is synthetically lethal with the loss of Rad54B-dependent recombination and is required for certain chromosome fusion events induced by telomere dysfunction

  2012cites this paper
• Live-Cell Microscopy Reveals Small Molecule Inhibitor Effects on MAPK Pathway Dynamics

  2011cites this paper
• Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer

  2010cites this paper
• Inhibiteurs de la voie Raf/MEK/ERK : synthèse de composés à structure 4-azaindolique et évaluation de leur efficacité par la mise au point de tests TR-FRET

  2010cites this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cites this paper
• PIK3CA alterations in Middle Eastern ovarian cancers

  2009cites this paper
• Oncogenic Activating Mutations Are Associated with Local Copy Gain

  2009cites this paper
• Gene Targeting in Human Somatic Cells

  2008cites this paper
• Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.

  2008cites this paper
• The Catalytic Subunit of DNA-Dependent Protein Kinase Regulates Proliferation, Telomere Length, and Genomic Stability in Human Somatic Cells

  2008cites this paper
• BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma

  2008cites this paper
• Ku70, an essential gene, modulates the frequency of rAAV-mediated gene targeting in human somatic cells

  2008cites this paper
• Lignées cellulaires humaines syngéniques comprenant des allèles de cancer mutés et procédé d’utilisation des lignées cellulaires

  2008cites this paper
• Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.

  2007cites this paper
• 53 Gene Targeting in Human Somatic Cells

  2007cites this paper
• Raf kinases: function, regulation and role in human cancer.

  2007cites this paper
• Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

  2007cites this paper
• Targeted Therapies in Combination with Chemotherapy in Non–Small Cell Lung Cancer

  2006cites this paper
• Activation of p 53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK 3 CA

  2006cites this paper
• Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA

  2006cites this paper
• Comparison of the Effects of Ras Effector Mutants and Ras Effectors on Transformed and Tumorigenic Growth of Human and Rodent Cells

  2006cites this paper
• CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45

  2006cites this paper
• Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.

  2006cites this paper
• Glutathione S-Transferase P 1 Promotes Tumorigenicity in HCT 116 Human Colon Cancer Cells

  2005cites this paper
• Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells.

  2005cites this paper
• Glutathione S-Transferase π1 Promotes Tumorigenicity in HCT116 Human Colon Cancer Cells

  2005cites this paper
• Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.

  2005cites this paper
• Raf kinase as a target for anticancer therapeutics

  2005cites this paper
• Glutathione S-Transferase P1 Promotes Tumorigenicity in HCT116 Human Colon Cancer Cells

  2005cites this paper